文献速递生殖医学

枸橼酸氯米芬与来曲唑在卵巢刺激中减少促卵泡激素用量的系统评价与荟萃分析

Clomiphene citrate and letrozole to reduce follicle-stimulating hormone consumption during ovarian stimulation: systematic review and meta-analysis.
PubMed 文献 · Ultrasound Obstet Gynecol · 2017-08-10

该系统评价与荟萃分析纳入22项随机对照试验,比较枸橼酸氯米芬(CC)和/或来曲唑(LTZ)减少促卵泡激素(FSH)用量的卵巢刺激方案与标准方案。在预期卵巢低反应妇女中,CC方案的活产率和临床妊娠率与标准方案相似;在其他妇女中,CC方案降低获卵数和卵巢过度刺激综合征(OHSS)风险,活产率和临床妊娠率相似。来曲唑减少FSH用量对获卵数无相关改变,仍需更多研究。

要点

  • 预期卵巢低反应妇女中,CC减少FSH用量的活产率(RR 0.9,95%CI 0.6-1.2)和临床妊娠率(RR 1.0,95%CI 0.8-1.4)与标准方案相似。
  • 其他妇女中,CC减少FSH用量降低获卵数(MD -4.6,95%CI -6.1至-3.0)和OHSS风险(Peto OR 0.2,95%CI 0.1-0.3),活产率和临床妊娠率相似。
  • 来曲唑减少FSH用量未导致获卵数相关改变(MD -0.4,95%CI -0.9至0.1),仍需更多研究评估其效果。

核心结论

  • 预期卵巢低反应妇女使用CC减少FSH用量可提供相似的生殖结局并降低成本。
  • 其他妇女使用CC减少FSH用量可额外降低OHSS风险,但也减少获卵总数。
  • 需要更多研究评估LTZ用于相同目的的效果。

研究设计与样本

  • 系统评价与荟萃分析,纳入比较体外受精后生殖结局的随机对照试验。
  • 检索11个电子数据库并手工检索纳入研究及相关综述的参考文献列表。
  • 按口服药物(CC或LTZ)和妇女特征(预期卵巢低反应或其他妇女)分层分析。
  • 共纳入22项研究。

主要发现

  • 预期卵巢低反应妇女中,CC减少FSH用量的活产率RR 0.9(95%CI 0.6-1.2),中等质量证据。
  • 预期卵巢低反应妇女中,CC减少FSH用量的临床妊娠率RR 1.0(95%CI 0.8-1.4),中等质量证据。
  • 预期卵巢低反应妇女中,LTZ减少FSH用量的获卵数MD -0.4(95%CI -0.9至0.1),高质量证据。
  • 其他妇女中,CC减少FSH用量的获卵数MD -4.6(95%CI -6.1至-3.0),高质量证据。
  • 其他妇女中,CC减少FSH用量的OHSS风险Peto OR 0.2(95%CI 0.1-0.3),中等质量证据。

关键数值与推荐

  • 其他妇女中,CC减少FSH用量的活产率RR 0.9(95%CI 0.7-1.1),中等质量证据。
  • 其他妇女中,CC减少FSH用量的临床妊娠率RR 1.0(95%CI 0.8-1.1),高质量证据。
  • 其他结局的证据质量低或极低。

临床怎么用

  • 作者认为,预期卵巢低反应妇女使用CC减少FSH用量具有提供相似生殖结局并降低成本的优点。
  • 作者认为,其他妇女使用CC减少FSH用量具有额外降低OHSS的优点,但也减少获卵总数。
  • 作者建议未来研究应关注每取卵周期的累积妊娠、患者不满和未妊娠时同意重复周期的意愿。

局限性

  • 其他结局的证据质量低或极低。
  • 需要更多研究评估LTZ用于相同目的的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the available evidence comparing effectiveness of ovarian stimulation (OS) using clomiphene citrate (CC) and/or letrozole (LTZ) to reduce follicle-stimulating hormone (FSH) consumption compared with standard OS. METHODS: We performed a systematic review and meta-analysis of randomized controlled trials that compared reproductive outcomes following in-vitro fertilization. We searched 11 electronic databases and hand-searched the reference lists of included studies and related reviews. We stratified the results, separating studies according to the oral agent used (CC or LTZ) and the characteristics of the included women (expected poor ovarian response or other women). When combining the results of the included studies, we assessed the relative risk (RR) for live birth, clinical pregnancy, miscarriage and cycle cancelation, the Peto odds ratio (OR) for ovarian hyperstimulation syndrome (OHSS) and mean difference (MD) for the number of oocytes retrieved and FSH consumption. RESULTS: A total of 22 studies were included in the review. Considering women with expected poor ovarian response, the available evidence suggested that using CC to reduce FSH consumption during OS provided similar rates of live birth (RR, 0.9 (95% CI, 0.6-1.2), moderate-quality evidence) and clinical pregnancy (RR, 1.0 (95% CI, 0.8-1.4), moderate-quality evidence); the use of LTZ did not cause a relevant change in the number of oocytes retrieved (MD, -0.4 (95% CI, -0.9 to 0.1), high-quality evidence). Considering the studies evaluating other women, the available evidence suggested that using CC to reduce FSH consumption during OS reduced the number of oocytes retrieved (MD, -4.6 (95% CI, -6.1 to -3.0), high-quality evidence) and risk of OHSS (Peto OR, 0.2 (95% CI, 0.1-0.3), moderate-quality evidence), while results were similar for rates of live birth (RR, 0.9 (95% CI, 0.7-1.1), moderate-quality evidence) and clinical pregnancy (RR, 1.0 (95% CI, 0.8-1.1), high-quality evidence). The quality of the evidence was low or very low for other outcomes. CONCLUSION: The use of CC to reduce FSH consumption in women with expected poor ovarian response has the advantage of providing similar reproductive outcomes with reduced costs. For the other women, the use of CC for reducing FSH consumption has the additional advantage of reducing OHSS, but also reduces the total number of oocytes retrieved. More studies are needed to evaluate the effect of LTZ for the same purpose. Future studies should focus on cumulative pregnancy per oocyte retrieval, patient dissatisfaction and agreement to repeat the cycle if not pregnant, which are important outcomes for clinical decisions. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Bechtejew TN, Nadai MN, Nastri CO, et al. Clomiphene citrate and letrozole to reduce follicle-stimulating hormone consumption during ovarian stimulation: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2017. PMID: 28236310. doi:10.1002/uog.17442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。